PSA decline is an independent prognostic marker in hormonally treated prostate cancer.

OBJECTIVE The aim of this study was to estimate the prevalence of primary hormone-refractory prostate cancer and to evaluate the prognostic value of decline of prostate-specific antigen (PSA) after primary hormonal therapy. MATERIAL AND METHODS The material consisted of 236 consecutive, hormonally treated prostate cancer patients, whose… CONTINUE READING